secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-108840
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel reports positive Phase 3 safety and efficacy results for BXCL501 agitation in home setting
--------------------------------------------------------------------------------

- BXCL501 (sublingual dexmedetomidine) safe and well-tolerated in 12-week home-use study (SERENITY At-Home).
- No increase in adverse events with repeat dosing; 81% of treated patients completed the study.
- Exploratory efficacy: greater reduction in mCGI-S vs placebo (P<0.05); complete resolution higher with BXCL501 (P<.0001).
- No patient on active arm discontinued due to TEAE; results support potential label expansion for unsupervised use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925108840/0001104659-25-108840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925108840/tm2530721d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-108840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer